Chemerin-9 (149-157) TFA 是趋化因子样受体1 (CMKLR1) 的有效激动剂。Chemerin-9 (149-157) TFA 具有抗炎活性。Chemerin-9 (149-157) TFA 刺激 Akt 和 ERK 的磷酸化以及活性氧的产生。Chemerin-9 (149-157) TFA 改善 Aβ1-42诱导的记忆障碍。Chemerin-9 (149-157) TFA 调节免疫反应、脂肪细胞分化和糖代谢。
| 生物活性 | Chemerin-9 (149-157) TFA is a potent agonist ofchemokine-like receptor 1 (CMKLR1). Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation ofAktandERKas well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism[1][2][3][4]. |
体外研究
(In Vitro) | Chemerin-9 (149-157) TFA (0.1 nM; 24 h; cardiac fibroblasts) stimulates migration in cardiac fibroblasts and stimulates phosphorylation of Akt and ERK as well as ROS production[4].
Western Blot Analysis[4] | Cell Line: | Cardiac fibroblasts | | Concentration: | 0.1 nM | | Incubation Time: | 24 hours | | Result: | Stimulated phosphorylation of Akt and ERK. |
|
体内研究
(In Vivo) | Chemerin-9 (149-157) TFA (0.2 mg/kg; i.p.; daily, for 42 days) alleviates glucose intolerance and IR in PDM mice[1].
Chemerin-9 (149-157) TFA (7.7 μg /kg; i.h.; daily, for 28 days) has anti-inflammatory and anti-angiogenic effects in ApoE-/-mice and protects the abdominal aorta from MMP damage[2].
Chemerin-9 (149-157) TFA (8 μg/kg; ICV; daily; for 14 d; male Kunming mice) ameliorates Aβ1-42-induced memory impairment[3].
| Animal Model: | PDM mice[1] | | Dosage: | 0.2 mg/kg | | Administration: | Intraperitoneal injection; daily, for 42 days | | Result: | Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice. |
| Animal Model: | ApoE-/-mice[2] | | Dosage: | 7.7 μg /kg | | Administration: | Subcutaneous injection; daily, for 28 days | | Result: | Suppressed the enlargement of abdominal aorta and reversed the SMC loss. |
| Animal Model: | ApoE-/-mice[2] | | Dosage: | 7.7 μg /kg | | Administration: | Subcutaneous injection; daily, for 28 days | | Result: | Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1. |
| Animal Model: | Male Kunming mice[3] | | Dosage: | 8 μg/kg | | Administration: | Intracerebroventrical injection; daily; for 14 days | | Result: | Increased in the levels of pro-inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| Sequence Shortening | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Sealed storage, away from moisture | Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: H2O : 100 mg/mL(84.95 mM;Need ultrasonic) 配制储备液 | 1 mM | 0.8495 mL | 4.2474 mL | 8.4949 mL | | 5 mM | 0.1699 mL | 0.8495 mL | 1.6990 mL | | 10 mM | 0.0849 mL | 0.4247 mL | 0.8495 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 |
m.cnreagent.com